Evidence map›Paper›PMID 26585352›Full record

ArticleThe Prostate2016

Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer.

Tobias Nordström, Erin L Van Blarigan, Vy Ngo, Ritu Roy, Vivian Weinberg, Xiaoling Song, Jeffry Simko, Peter R Carroll, June M Chan, Pamela L Paris

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Prostate, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. [Complementary medicine in uro-oncology].Der Urologe. Ausg. A · 2021
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Tobias NordströmDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
Erin L Van BlariganDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
Vy NgoDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
Ritu RoyComputational Biology Core, Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Vivian WeinbergBiostatistics Core, Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
Xiaoling SongCancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jeffry SimkoDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
Peter R CarrollDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
June M ChanDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
Pamela L ParisDepartment of Urology, Helen Diller Family Comprehensive Cancer Research Center, University of California, San Francisco, California.
UCSF Helen Diller Family Comprehensive Cancer Center · USCancer Research Center · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAKarolinska Institutet · SEUniversity of California, San Francisco · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Training in Molecular& Genetic Epidemiology of CancerR25CA112355 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WITTE, JOHN S. · 2005 to 2018
$6.5M
Prostate Microenvironmental & Prostate Cancer ProgressionR01CA106947 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHAN, JUNE ML · 2006 to 2009
$1.5M
NCI NIH HHS P30 CA082103NCI NIH HHS R01 CA106947NCI NIH HHS R01 CA106947-01A1NCI NIH HHS R25 CA112355
6 · The paper itself

Abstract

backgroundCarotenoids are a class of nutrients with antioxidant properties that have been purported to protect against cancer. However, the reported associations between carotenoids and prostate cancer have been heterogeneous and lacking data on interactions with nucleotide sequence variations and genomic biomarkers.

objectiveTo examine the associations between carotenoid levels and the risk of high-grade prostate cancer, also considering antioxidant-related genes and tumor instability.

methodsWe measured plasma levels of carotenoids and genotyped 20 single nucleotide polymorphisms (SNP) in SOD1, SOD2, SOD3, XRCC1, and OGG1 among 559 men with non-metastatic prostate cancer undergoing radical prostatectomy. We performed copy number analysis in a subset of these men (n = 67) to study tumor instability assessed as Fraction of the Genome Altered (FGA). We examined associations between carotenoids, genotypes, tumor instability and risk of high-grade prostate cancer (Gleason grade ≥ 4 + 3) using logistic and linear regression.

resultsCirculating carotenoid levels were inversely associated with the risk of high-grade prostate cancer; odds ratios (OR) and 95% confidence intervals (CI) comparing highest versus lowest quartiles were: 0.34 (95% CI: 0.18-0.66) for α-carotene, 0.31 (95% CI: 0.15-0.63) for β-carotene, 0.55 (0.28-1.08) for lycopene and 0.37 (0.18-0.75) for total carotenoids. SNPs rs25489 in XRCC1, rs699473 in SOD3 and rs1052133 in OGG1 modified these associations for α-carotene, β-carotene and lycopene, respectively (P ≤ 0.05). The proportion of men with a high degree of FGA increased with Gleason Score (P < 0.001). Among men with Gleason score ≤ 3 + 4, higher lycopene levels were associated with lower FGA (P = 0.04).

conclusionCirculating carotenoids at diagnosis, particularly among men carrying specific somatic variations, were inversely associated with risk of high-grade prostate cancer. In exploratory analyses, higher lycopene level was associated with less genomic instability among men with low-grade disease which is novel and supports the hypothesis that lycopene may inhibit progression of prostate cancer early in its natural history.

Indexed as

AgedAntioxidantsbeta CaroteneCarotenoidsCross-Sectional StudiesDNA RepairGenomic InstabilityGenotypeHumansLycopeneMaleMiddle AgedNeoplasm GradingOdds RatioPolymorphism, Single NucleotideProstatealpha-caroteneAntioxidantsbeta CaroteneCarotenoidsLycopeneSuperoxide Dismutasecarotenesgenetic polymorphismsgenomic instabilitylycopeneprostate cancer

Identifiers

PMID26585352
PMCPMC5493324
OpenAlexW2214622128

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.